Positive family history is a significant risk factor for prostate cancer. Improved knowledge of the epidemiology and molecular basis of hereditary prostate cancer has led to a need for counseling and clinical follow-up for men with a positive family history of prostate cancer. However, very little information is available on the efficacy of early screening procedures, such as serum prostate-specific antigen (PSA) measurements, in the management of genetically predisposed, high-risk individuals. In a nationwide study, we obtained family histories from 2099 Finnish prostate cancer patients and identified 302 families with two or more affected cases. Here, 209 asymptomatic 45–75-year-old males from these families were included in a study to determine the frequency of serum PSA positivity and the prevalence of subclinical prostate cancers. Serum PSA was elevated in 21 (10.0%) of these high-risk individuals. Seven prostate cancers (3.3%) and two high-grade prostatic intraepithelial neoplasia lesions were diagnosed, with three cancers occurring in men ages ≤59 years. Men from prostate cancer families with an average age of onset of <60 years had a significantly higher frequency of PSA positivity (28.6%, P = 0.01) as well as cancers (14.3%, P = 0.02) than those with a later age of onset. The results suggest that prostate cancer development in genetically predisposed individuals is preceded by a subclinical period when PSA detection is possible. Serum PSA screening may be particularly useful in men with a family history of early-onset prostate cancer.

Prostate cancer is the most common malignancy in men in many industrialized countries. For example, in Finland, prostate cancer comprised 24.6% of all malignancies in men in 1995, with an age-adjusted incidence of 61.4 per 100,000 men. It was second only to lung cancer as a cause of cancer mortality (1). Positive family history is one of the strongest risk factors for prostate cancer (2). Approximately 5–10% of prostate cancer cases may be influenced by a germ-line predisposition (3, 4). Men with a positive family history have 2–10 times increased prostate cancer risks compared to those with no family history. The risk ratios are highest in families with multiple prostate cancer cases and in those in which the average age of cancer diagnosis is low (3, 4, 5).

The first gene conferring susceptibility to prostate cancer (HPC1) was recently mapped to chromosome region 1q24–q25 (6). Genetic linkage data suggest that it contributes to a fraction of early-onset prostate cancer families (7). HPC1 gene carriers may have a 60–90% lifetime risk of prostate cancer. Two other loci for prostate cancer predisposition, one at 1q42 (8) and another (HPCX) at Xq27–28 (9), were also reported recently. The relative impact of these three loci remains to be determined (10, 11). Furthermore, polymorphisms of several genes, such as androgen receptor, 5α-reductase, and vitamin D receptor may also influence the risk of prostate cancer (12, 13, 14). Further studies of such genetic risk indicators may eventually enable development of genetic testing for prostate cancer (6). However, awareness of inherited cancer risks is already increasing among urologists, patients, and their relatives. Consequently, a need for counseling and clinical follow-up for men with a strong family history of disease is emerging (15).

Serum PSA3 measurements and clinical examination are important strategies to screen for the presence of asymptomatic prostate cancer (16, 17, 18). PSA is highly sensitive in detecting subclinical prostate cancers, defined here as cancers causing no clinical symptoms, but its utility in reducing mortality is still under investigation. The efficacy of PSA screening in high-risk subgroups, such as those with a positive family history, has received very little attention (19, 20). Assuming that men with a strong family history have substantially increased risk of prostate cancer, these high-risk men may also have a high prevalence of subclinical, PSA-detectable prostate cancer. This study was aimed at testing this hypothesis. In this study, 209 asymptomatic men from a nationwide material of 302 prostate cancer families in Finland were analyzed to determine the frequencies of elevated PSA values and of subclinical prostate cancer.

We identified 302 prostate cancer families in Finland with two or more affected first- or second-degree relatives per family. A number of different methods for family ascertainment were used to obtain coverage of the entire country: (a) a nationwide cancer and parish registry based search was performed to uncover family history of 1547 prostate cancer patients diagnosed between 1988 and 1993 (including all 557 cases of prostate cancer diagnosed at the age of ≤60 years); (b) advertisements in newspapers, radio, and television resulted in 500 contacts with patients and their relatives; and (c) letters to practicing urologists resulted in 52 contacts with patients or family members. Diagnosis of cancer in the relatives was confirmed by information from hospital records or the Finnish Cancer Registry. Altogether, family history was obtained from 2099 men with prostate cancer. On the basis of the substantial overlap of families identified by the registry-based search4 and by other methods, the 302 families identified should represent a large fraction of all prostate cancer families in Finland. Of these families, 103 were selected for this study based on the criterion that at least one unaffected first-degree male relative ages >44 years was available.

The study material consisted of 226 unaffected first-degree male relatives from the 103 families, of which 209 (107 brothers and 102 sons of probands) agreed to participate (92.5%) and gave written informed consent. One 10-ml blood specimen was obtained for DNA isolation, and another 10-ml specimen was obtained to prepare serum for PSA measurement. The mean age of the 209 unaffected men was 56.0 years (range, 45–75 years). The mean number of unaffected cases studied per family was 2.0 (range, 1–9). One hundred twenty men came from families with three to seven prostate cancers, and 89 came from families with two affected cases. The mean age of diagnosis of prostate cancer in these families was 69.7 years (range, 55–86 years).

Serum specimens were stored at −70°C until analyzed, for a maximum of 8 weeks. The AutoDELFIA PSA kit (Wallac, Turku, Finland) was used to determine total serum PSA concentrations. Age-specific reference values were used as a criterion for cutoff values of raised serum PSA levels. These reference values are used in the clinical routine at the Tampere University Hospital and are based on the results from the Gothenburg (21) and Rotterdam (22, 23) European Organization for Research and Treatment of Cancer screening studies with 5845 and 1726 unselected participants, respectively (95th percentile of the distribution). If serum PSA was elevated, the subject was referred to a local urology department for subsequent urological examination, which included a new PSA measurement, digital rectal examination, ultrasound, and one set of random biopsies.

Statistical analyses were performed using Fisher’s exact test, calculated with GraphPad Instat 228 software (GraphPad Software, San Diego, CA).

Twenty-one of the 209 apparently healthy men (10.0%) from prostate cancer families had elevated serum PSA values compared to age-specific reference values (Fig. 1). The elevated values ranged from 2.6 to 28.3 mg/liter. Subsequent urological examination with first set of random biopsies revealed seven patients (3.3%) with prostate adenocarcinoma (Fig. 1 and Table 1) and two (1.0%) with PIN. One of the cancers was in the advanced stage, whereas the others were intracapsular (Table 1). The mean age of the PSA-detected cancer patients was 65.1 years (range 52–75), which is approximately seven years lower than the average age of diagnosis of prostate cancer patients in Finland. Three of the cases (43% of all screen-detected cases) were detected under the age of 60 years.

The frequency of PSA positivity (28.6%) and subclinical prostate cancer (14.3%) were significantly higher (P = 0.010 for PSA and P = 0.024 for cancer by Fisher’s exact test) in men from families with an average age of onset of ≤60 years, as compared to those from families with a mean age of onset of >60 years (Fig. 2). Furthermore, five of the seven new prostate cancers found in this screening study came from large families in which three or more men were previously known to be affected with prostate cancer (Fig. 3). Overall, six of the seven new cancer cases detected were detected in families that had either an average age of onset of <60 years or three or more previous known affected cases.

The overall frequency of subclinical cancers (3.3%) detected in asymptomatic men from prostate cancer families was similar to that reported (2.3–4.5%) in PSA screening studies of unselected populations (17, 18, 23, 24, 25). However, in men from early-onset prostate cancer families, cancer detection frequency was significantly higher, up to 14%. The high frequency of PSA-detectable cancer in men from early-onset prostate cancer families is in an excellent agreement with epidemiological data on familial cancer risks (3, 4, 5, 26, 27, 28, 29, 30, 31). Men with a positive family history of prostate cancer are known to have 2–10 times higher risk of prostate cancer compared to those with no family history. This risk is influenced by the number of affected family members and particularly strongly by the average age of diagnosis of prostate cancer in the family. Taken together, our experimental results and the aforementioned epidemiological studies strongly support the concept that serum PSA screening is likely to be particularly useful in men with a family history of early-onset prostate cancer.

The number of prostate cancers detected in our study group was ∼21 times higher than the expected annual number (0.3), as determined from age-adjusted incidence rates in the Finnish population (1). Such a high cancer detection frequency most likely reflects the fact that serum PSA screening is known to advance diagnosis of prostate cancer by 5–10 years as compared to clinical detection (32). In this study, only one set of random biopsies was performed for the patients with elevated PSA. It is known that with follow-up biopsies additional cancers are often detected (33). This suggests that the frequencies obtained in this study are likely to underestimate the true prevalence of subclinical prostate cancer. These results indicate suggest that prostate cancer development in genetically predisposed individuals is also preceded by a subclinical period when PSA detection may be possible. Detection of such subclinical cancers in these high-risk individuals may be useful because it may provide a chance for early treatment and cure.

Two previous studies have investigated serum PSA levels in relation to positive family history. In the study by McWhorter et al.(19), 34 apparently healthy, 55–80-year-old, first-degree male relatives from 17 prostate cancer families were studied. Proportion of elevated PSA levels in the study by McWhorter et al. (19) was 17.6% (cutoff levels, 4.0 ng/ml), and cancer detection frequency was 8.8% (three cases). In addition, five additional cancers (14.7%) were detected by digital rectal examination, ultrasound, and biopsies. In the study by Narod et al.(20), 6390 unselected men ages 50–80 years were screened by PSA and rectal examination. Prostate cancer was detected in 10.2% of subjects who reported a brother and in 4.8% of those who had a father with prostate cancer. Only 3.9% of men with no first-degree relatives had subclinical prostate cancer. Our material differs from those of Narod et al.(20) and McWhorter et al.(19) in that several extended pedigrees were included, that the mean age of subjects (56.0 years; range, 45–75 years) was lower, and that cancer diagnoses were verified independently (in contrast to subjective family questionnaires). Especially when the age differences are taken into account, the 3.3% prevalence of subclinical cancers in our study is comparable with the two previous studies.

Despite the substantial progress in dissecting the molecular basis of prostate cancer predisposition (6, 8, 9), it will take many years before specific genetic tests will be commonly available. Therefore, PSA screening is likely to have an important role in alleviating concerns of cancer in members of prostate cancer families who seek medical attention and genetic counseling. At the time being, long-term clinical follow-up procedures should probably be limited to men from those families in which the age of onset of prostate cancer is <60 years or three or more prostate cancers have been previously already diagnosed. Because half of the new cancer cases in our study were detected in 50–59-year-old men, PSA screening of high-risk groups should commence early, perhaps at the age of 45 years, as suggested by Walsh and Partin (34).

Finally, these results emphasize the importance of including PSA screening in genetic linkage studies of prostate cancer susceptibility. In all seven families in which new prostate cancer cases were diagnosed based on this PSA screening, logarithm of the odds ratio for linkage (lod) scores obtained for HPC1 (or for any other locus tested) were substantially influenced by the inclusion of these PSA-detected cases as affected cases in these pedigrees.

In conclusion, serum PSA screening may have utility in the management and follow-up of unaffected male individuals in prostate cancer families with an early age of cancer diagnosis. Because several cancers were diagnosed in 50–59-year-old men, PSA screening in high-risk groups should be started at an early age. Further research is required to establish how often PSA screening should be repeated and whether such a targeted and repeated screening affects the mortality or improves the quality of life of men with positive family history of prostate cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

        
1

This work was supported by grants from the Reino Lahtikari Foundation, the Medical Research Fund of Tampere University Hospital, the Finnish Cancer Society, the Sigrid Juselius Foundation, and the Academy of Finland. The original family collection was funded in part by federal funds from the National Center for Human Genome Research, NIH (Contract N01-HG-55389). In addition, M. P. M. received support from the Pirkanmaa Cancer Society.

                
3

The abbreviations used are: PSA, prostate-specific antigen; PIN, prostatic intraepithelial neoplasia.

        
4

M. P. Matikainen et al., Risk of prostate and other cancers in first-degree relatives of prostate cancer patients: a registry-based analysis in Finland, manuscript in preparation.

Fig. 1.

Distribution of serum PSA values in asymptomatic men from prostate cancer families with age-specific cutoff values (horizontal lines). ▴, prostate cancer cases.

Fig. 1.

Distribution of serum PSA values in asymptomatic men from prostate cancer families with age-specific cutoff values (horizontal lines). ▴, prostate cancer cases.

Close modal
Fig. 2.

Percentage of PSA-positive cases and prostate cancers diagnosed in asymptomatic men from prostate cancer families divided according to the mean age at diagnosis of prostate cancer in family. **, P < 0.01; *, P < 0.05

Fig. 2.

Percentage of PSA-positive cases and prostate cancers diagnosed in asymptomatic men from prostate cancer families divided according to the mean age at diagnosis of prostate cancer in family. **, P < 0.01; *, P < 0.05

Close modal
Fig. 3.

Two examples of prostate cancer families with new cancer cases detected by PSA screening. ▪, men with prostate cancer (numbers, ages of diagnosis); □, unaffected cases; , men with PIN lesions. Arrows, cancer and PIN cases detected by PSA screening. The serum PSA concentration (μg/liter) at diagnosis is indicated.

Fig. 3.

Two examples of prostate cancer families with new cancer cases detected by PSA screening. ▪, men with prostate cancer (numbers, ages of diagnosis); □, unaffected cases; , men with PIN lesions. Arrows, cancer and PIN cases detected by PSA screening. The serum PSA concentration (μg/liter) at diagnosis is indicated.

Close modal
Table 1

New cases of prostate cancer detected in this study by PSA screening of prostate cancer families

Case no.Age (yr)No. of previous CaPa cases in familyMean age at diagnosis of CaP in family, yr (range)Serum PSA (μg/liter)HistologyTNMGrade
68 68.3 (63–74) 10.7 Prostate adenocarcinoma T1cN0M0 
59 58.3 (56–60) 4.6 Prostate adenocarcinoma T1cN0M0 
75 58.7 (52–65) 13.5 Prostate adenocarcinoma T1cNxM0 
73 74.3 (55–93) 15.7 Prostate adenocarcinoma T1cNxM0 
72 65.7 (50–79) 28.3 Prostate adenocarcinoma T3N2M1 III 
52 57.0 (57–57) 3.9 Prostate adenocarcinoma T1cN0M0 
57 82.5 (82–83) 12.1 Prostate adenocarcinoma T1cN0M0 
Case no.Age (yr)No. of previous CaPa cases in familyMean age at diagnosis of CaP in family, yr (range)Serum PSA (μg/liter)HistologyTNMGrade
68 68.3 (63–74) 10.7 Prostate adenocarcinoma T1cN0M0 
59 58.3 (56–60) 4.6 Prostate adenocarcinoma T1cN0M0 
75 58.7 (52–65) 13.5 Prostate adenocarcinoma T1cNxM0 
73 74.3 (55–93) 15.7 Prostate adenocarcinoma T1cNxM0 
72 65.7 (50–79) 28.3 Prostate adenocarcinoma T3N2M1 III 
52 57.0 (57–57) 3.9 Prostate adenocarcinoma T1cN0M0 
57 82.5 (82–83) 12.1 Prostate adenocarcinoma T1cN0M0 
a

CaP, prostate cancer; TNM, tumor-node-metastasis.

All patients and families participating this study are cordially thanked for their cooperation. We thank Kaisa Vaherto for technical assistance and Dr. Pasi Koivisto for comments. The following colleagues and institutions are acknowledged for their cooperation: Dr. Mirja Ruutu from the Department of Urology, Helsinki University Hospital; Dr. Martti Ala-Opas from the Department of Urology, Kuopio University Hospital; Drs. Jukka Kallio, Christian Palmberg, Taina Isotalo, and Susanna Laaksovirta from the Department of Urology, Tampere University Hospital; Dr. Matti Rauvala from the Department of Urology, Rovaniemi Central Hospital; Dr. Martti Talja from the Department of Urology, Päijät-Häme Central Hospital; Dr. Kari Jauhiainen from the Department of Urology, Mikkeli Central Hospital; Dr. Eero Kaasinen from the Department of Surgery, Hyvinkää District Hospital; Dr. Jukka Kärki from the Department of Surgery, Salo District Hospital; Dr. Asko Heikkinen from the Department of Surgery, Valkeakoski District Hospital; and Dr. Erkki Rintala from the Department of Urology, Helsinki City Hospital.

1
Finnish Cancer Registry. Cancer Incidence in Finland 1995: Cancer Statistics of the National Research and Development Centre for Welfare and Health. Cancer Society of Finland, Publ. No. 58. Helsinki, Finland, 1997.
2
Carter B. S., Beaty T. H., Steinberg G. D., Childs B., Walsh P. C. Mendelian inheritance of familial prostate cancer.
Proc. Natl. Acad. Sci. USA
,
89
:
3367
-3371,  
1992
.
3
Carter B. S., Bova G. S., Beaty T. H., Steinberg G. D., Childs B., Isaacs W. B., Walsh P. C. Hereditary prostate cancer: epidemiologic and clinical features.
J. Urol.
,
150
:
797
-802,  
1993
.
4
Goldgar D. E., Easton D. F., Cannon-Albright L. A., Skolnick M. H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.
J. Natl. Cancer Inst. (Bethesda)
,
86
:
1600
-1607,  
1994
.
5
Grönberg H., Damber L., Damber J. E. Familial prostate cancer in Sweden: a nationwide register cohort study..
Cancer (Phila.)
,
77
:
138
-143,  
1996
.
6
Smith J. R., Freije D., Carpten J. D., Grönberg H., Xu J., Isaacs S. D., Brownstein M. J., Bova G. S., Guo H., Bujnovszky P., Nusskern D. R., Damberg J-E., Bergh A., Emanuelsson M., Kallioniemi O-P., Walker-Daniels J., Bailey-Wilson J. E., Beaty T. H., Meyers D. A., Walsh P. C., Collins F. S., Trent J. M., Isaacs W. B. A genome wide search reveals a major susceptibility locus for prostate cancer on chromosome 1.
Science (Washington DC)
,
274
:
1371
-1374,  
1996
.
7
Grönberg H., Isaacs S. D., Smith J. R., Carpten J. D., Xu J., Bova G. S., Freije D., Meyers D. A., Collins F. S., Trent J. M., Walsh P. C., Isaacs W. B. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus.
J. Am. Med. Assoc.
,
278
:
1251
-1255,  
1997
.
8
Berthon P., Valeri A., Cohen-Akenine A., Drelon E., Paiss T., Wöhr G., Latil A., Millasseau P., Mellah I., Cohen N., Blanche H., Bellane-Chantelot C., Demenais F., Teillac P., Le Duc A., de Petriconi R., Hautmann R., Chumakov I., Bachner L., Maitland N. J., Lidereau R., Vogel W., Fournier G., Mangin P., Cohen D., Cussenot O. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2–43.
Am. J. Hum. Genet.
,
62
:
1416
-1424,  
1998
.
9
Xu J., Meyers D., Freije D., Isaacs S., Wiley K., Nusskern D., Ewing C., Wilkens E., Bujnovszky P., Bova G. S., Walsh P., Isaacs W., Schleutker J., Matikainen M., Tammela T., Visakorpi T., Kallioniemi O-P., Berry R., Schaid D., French A., McDonnell S., Schroeder J., Blute M., Thibodeau S., Grönberg H., Emanuelsson M., Damber J-E., Bergh A., Jonsson B-A., Smith J., Bailey-Wilson J., Carpten J., Stephan D., Gillanders E., Amundson I., Kainu T., Freas-Lutz D., Baffoe-Bonnie A., Van Aucken A., Sood R., Collins F., Brownstein M., Trent J. Evidence for a prostate cancer susceptibility locus on the X chromosome.
Nat. Genet.
,
20
:
175
-179,  
1998
.
10
Cooney K. A., McCarthy J. D., Lange E., Huang L., Miesfeldt S., Montie J. E., Oesterling J. E., Sandler H. M., Lange K. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study.
J. Natl. Cancer Inst. (Bethesda)
,
89
:
955
-958,  
1997
.
11
Hsieh C. L., Oakley-Girvan I., Gallagher R. P., Wu A. H., Kolonel L. N., The C. Z., Halpern J., West D. W., Paffenbarger R. S., Jr., Whittemore A. S. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study.
J. Natl. Cancer Inst. (Bethesda)
,
89
:
1893
-1894,  
1997
.
12
Giovannucci E., Stampfer M. J., Krithivas K., Brown M., Brufsky A., Talcott J., Hennekens C. H., Kantoff P. W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.
Proc. Natl. Acad. Sci. USA
,
94
:
3320
-3323,  
1997
.
13
Reichardt J. K. V., Makridakis N., Henderson B. E., Yu M. C., Pike M. C., Ross R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.
Cancer Res.
,
55
:
3973
-3975,  
1995
.
14
Taylor J. A., Hirvonen A., Watson M., Pittman G., Mohler J. L., Bell D. A. Association of prostate cancer with vitamin D receptor gene polymorphism.
Cancer Res.
,
56
:
4108
-4110,  
1996
.
15
Bratt O., Kristofferson U., Lundgren R., Olsson H. Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening and genetic testing.
Urology
,
50
:
360
-365,  
1997
.
16
Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate specific antigen in serum as a screening test for prostate cancer.
N. Engl. J. Med.
,
342
:
1156
-1161,  
1991
.
17
Labrie F., Dupont A., Suburu R., Cusan L., Tremblay M., Comez J-L., Emond J. Serum prostate specific antigen as pre-screening test for prostate cancer.
J. Urol.
,
147
:
846
-852,  
1992
.
18
Auvinen A., Tammela T., Stenman U.-H., Uusi-Erkkilä I., Leinonen J., Schröder F. H., Hakama M. Screening for prostate cancer using serum prostate specific antigen: a randomised, population-based pilot study in Finland.
Br. J. Cancer
,
74
:
568
-572,  
1996
.
19
McWhorter W. P., Hernandez A. D., Meikle A. W., Terreros D. A., Smith J. A., Jr., Skolnick M. H., Cannon-Albright L. A., Eyre H. J. A screening study of prostate cancer in high risk families.
J. Urol.
,
148
:
826
-828,  
1992
.
20
Narod S. A., Dupont A., Cusan L., Diamond P., Gomez J-L., Suburu R., Labrie F. The impact of family history on early detection of prostate cancer.
Nat. Med.
,
1
:
99
-101,  
1995
.
21
Hugonsson J., Aus G., Bergdahl S., Frösing R., Lodding P., Fernlund P., Lilja H. The value of the ratio of free/total PSA in screening for prostate cancer, preliminary data from Gothenburg screening study for prostate cancer.
J. Urol. Suppl.
,
157
:
118
1997
.
22
Bangma C. H., Rietberger J. B. W., Schröder F. H. Prostate-specific antigen as a screening test. The Netherlands experience.
Urol. Clin. North Am.
,
24
:
307
-314,  
1997
.
23
Standaert B., Denis L. The European randomized study of screening for prostate cancer: an update.
Cancer (Phila.)
,
80
:
1830
-1834,  
1997
.
24
Catalona W. J., Smith D. S., Ratliff T. L., Basler J. W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.
J. Am. Med. Assoc.
,
270
:
948
-954,  
1993
.
25
Mettlin C., Murphy G. P., Babaian R. J., Chesley A., Kane R. A., Littrup P. J., Mostofi F. K., Ray P. S., Shanberg A. M., Toi A. The results of a five-year early prostate cancer detection intervention.
Cancer (Phila.)
,
77
:
150
-159,  
1996
.
26
Woolf C. M. An investigation of the familial aspects of carcinoma of the prostate.
Cancer (Phila.)
,
13
:
739
-744,  
1960
.
27
Cannon L., Bishop D. T., Skolnick M., Hunt S., Lyon J. L., Smart C. R. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy.
Cancer Surv.
,
1
:
47
-69,  
1982
.
28
Meikle A. W., Smith J. A., West D. W. Familial factors affecting prostatic cancer risk and plasma sex-steroid levels.
Prostate
,
6
:
121
-128,  
1985
.
29
Monroe K. R., Yu M. C., Kolonel L. N., Coetzee G. A., Wilkens L. R., Ross R. K., Henderson B. E. Evidence of an X-linked or recessive genetic component to prostate cancer risk.
Nat. Med.
,
1
:
827
-829,  
1995
.
30
Lesko S. M., Rosenberg L., Shapiro S. Family history and prostate cancer risk.
Am. J. Epidemiol.
,
144
:
1041
-1047,  
1996
.
31
Neuhausen S. L., Skolnick M. H., Cannon-Albright L. Familial prostate cancer studies in Utah.
Br. J. Urol.
,
79 (Suppl. 1)
:
15
-20,  
1997
.
32
Stenman U-H., Hakama M., Knekt P., Aromaa A., Teppo L., Leinonen J. Serum concentrations of prostate specific antigen and its complex with a1-antichymotrypsin before diagnosis of prostate cancer.
Lancet
,
344
:
1594
-1598,  
1994
.
33
Keetch D. W., Catalona W. J., Smith D. S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.
J. Urol.
,
151
:
1571
-1574,  
1994
.
34
Walsh P. C., Partin A. W. Family history facilitates the early diagnosis of prostate carcinoma.
Cancer (Phila.)
,
80
:
1871
-1874,  
1997
.